Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix

Real-Time Planning for Ultrasound-Guided Brachytherapy with Data Analysis Tool Designed to Reduce Clutter

By Medimaging International staff writers
Posted on 04 Dec 2013
Print article
To support real-time planning for ultrasound-guided brachytherapy, a new application’s modular design reports the angular and linear position intraoperatively direct to the manufacturer’s treatment planning software. Through direct communication, the new device offers rapid connection for data analysis and reduces disorder in the surgical suite.

Civco Medical Solutions (Coralville, IA, USA) furthers real-time planning capabilities with US Food and Drug Administration (FDA) 510(k) clearance of the EX3 Stepper for low dose rate (LDR) and high dose rate (HDR) ultrasound-guided brachytherapy for prostate cancer detection and treatment. The unique design of the stepper also features a removable electronic unit, which mitigates the risk of damaging transmission components and reduces cleaning time after the procedure.

LDR prostate brachytherapy involves internal radiotherapy where tiny radioactive “seeds” are delivered through a needle and are permanently placed into or near the tumor for treatment. HDR prostate brachytherapy is a similar internal treatment that involves the temporary placement of a tiny radioactive source directly into the tumor or near the targeted treatment area.

Civco’s EX3 Stepper, similar to its predecessor the EXII, provides compatibility for BK Medical, GE Healthcare, Hitachi Aloka, and Siemens transrectal ultrasound probes and it is currently validated for use with Varian Vitesse and VariSeed treatment-planning software.
In addition to receiving FDA 510(k) clearance, CIVCO has also CE Marked the EX3 for sale in the European Union and other countries where the CE Mark is recognized.

Related Links:

Civco Medical Solutions



Print article
Radcal

Channels

Industry News

view channel

Global Ultrasound Devices Market Worth USD 3,860 Million By 2021

The global ultrasound devices market was valued at USD 3,216 million in 2015, and is estimated to grow at a CAGR of 3% between 2016 and 2021 to reach USD 3,860 million by 2021, driven by improvements in the ultrasound technology. These are the findings of Mordor Intelligence (Hyderabad, India), a global market research... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.